Ranibizumab for Edema of the mAcula in Diabetes: Protocol 4 With Tocilizumab: The READ-4 Study
NCT ID: NCT02511067
Last Updated: 2023-08-15
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
WITHDRAWN
Clinical Phase
PHASE2
Study Classification
INTERVENTIONAL
Study Start Date
2016-10-01
Study Completion Date
2016-10-05
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The purpose of this study is to investigate the safety, tolerability and efficacy of Ranibizumab and Tocilizumab alone and in combination in eyes with Diabetic Macular Edema.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Ranibizumab for Edema of the mAcula in Diabetes-2 (READ-2) Study
NCT00407381
Diabetic Macular Edema
COMPLETED
PHASE2
Ranibizumab in Residual Diabetic Macular Edema Following Previous Anti-VEGF Therapy
NCT01472510
Diabetic Macular Edema
COMPLETED
PHASE2
Ranibizumab for Edema of the Macula in Diabetes: Protocol 3 With High Dose - the READ 3 Study
NCT01077401
Diabetic Macular Edema
COMPLETED
PHASE2
A Efficacy and Safety Study of Ranibizumab 10mg/ml Injection (Incepta) in Patients With Diabetic Macular Edema
NCT06305416
Diabetic Macular Edema
Diabetic Retinopathy
Macular Edema
+3 more
RECRUITING
PHASE3
Safety and Efficacy of Ranibizumab in Diabetic Macular Edema
NCT01131585
Visual Impairment Due to Diabetic Macular Edema
TERMINATED
PHASE3
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This study will evaluate the safety of intravenous (IV) infusions of Tocilizumab in the treatment of subjects with diabetic macular edema (DME) as monotherapy and in combination with intravitreal (IVT) Ranibizumab. It will also evaluate the percentage change in central retinal thickness (CRT) from baseline (BL) to Month 6 in the study eye as assessed by spectral-domain optical coherence tomography (SD-OCT). Other study objectives are to determine: the change in visual acuity (VA) from baseline to Months 3, 6 and 12, the change in CRT from baseline to Months 3, 6 and 12 in all the three treatment arms and determine the number of eyes requiring rescue therapy.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Diabetic Macular Edema
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
FACTORIAL
Primary Study Purpose
TREATMENT
Blinding Strategy
SINGLE
Investigators
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Ranibizumab 0.3 mg
Mandatory monthly treatments with Intravitreal (IVT) ranibizumab (0.3 mg) starting at Baseline (BL) until Month 6. Starting at Month 6, treatments will be administered on as-needed basis, based on retreatment criteria.
Group Type
ACTIVE_COMPARATOR
Ranibizumab
Intervention Type
DRUG
Intravitreal injection of Ranibizumab (0.3mg)
Tocilizumab (8.0 mg/kg)
Mandatory monthly Intravenous (IV) infusions with tocilizumab (8.0 mg/kg) starting at Baseline (BL) until Month 6. Starting at Month 6, treatments will be administered on as-needed basis with IVT ranibizumab (0.3 mg), based on the retreatment criteria.
Group Type
EXPERIMENTAL
Tocilizumab
Intervention Type
DRUG
Intravenous Infusion of Tocilizumab ( 8.0 mg/kg)
Tocilizumab (8.0 mg /kg) plus Ranibizumab 0.3 mg
Mandatory Intravitreal (IVT) ranibizumab 0.3 mg at Baseline (BL) followed with an IV infusion of tocilizumab (8.0 mg/kg) on same day starting at Baseline (BL) until Month 6. Combination treatments (IVT ranibizumab 0.3 mg followed by IV tocilizumab 8.0 mg/kg infusion administered at same visit) will be given every month until Month 6. Starting at Month 6, treatments will continue to be administered on as-needed basis with IVT ranibizumab (0.3 mg), based on retreatment criteria.
Group Type
EXPERIMENTAL
Tocilizumab
Intervention Type
DRUG
Intravenous Infusion of Tocilizumab ( 8.0 mg/kg)
Ranibizumab
Intervention Type
DRUG
Intravitreal injection of Ranibizumab (0.3mg)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Tocilizumab
Intravenous Infusion of Tocilizumab ( 8.0 mg/kg)
Intervention Type
DRUG
Ranibizumab
Intravitreal injection of Ranibizumab (0.3mg)
Intervention Type
DRUG
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Actemra
Lucentis, Susvimo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* • Signed informed consent and authorization of use and disclosure of protected health information
* Age ≥18 years
* Diagnosis of diabetes mellitus (type 1 or type 2)
* Serum HbA1c ≥ 5.5% and ≤10% within 12 months of randomization. (It is important to be certain that the patients in the READ-4 Study have diabetes, which will suggest that the macular edema is secondary to diabetes. The American Diabetes Association has suggested that a HbA1c ≥ 5.5% may suggest the presence of diabetes mellitus.)
* Have diabetic macular edema (DME) with central subfield thickness of ≥ 310 microns on spectral domain optical coherence tomography (SD-OCT).
* Retinal thickening secondary to diabetes mellitus involving the center of the fovea (centered-involved macular edema).
* Best corrected visual acuity score in the study eye of 20/32 to 20/400 inclusive (Snellen equivalents using the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol at a distance of 4 meters). If both eyes are eligible, the investigator will select the eye to be enrolled as the study eye. There is no specific visual acuity requirement for the fellow eye at time of study eye enrollment. However, if the fellow eye is to receive ranibizumab, it must have an entry visual acuity of 20/32 to 20/400 inclusive (Snellen equivalents using the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol at a distance of 4 meters) at the time of the initial treatment.
* In the opinion of the investigator, decreased vision in the study eye is due to foveal thickening from diabetic macular edema (DME) and not from other obvious causes of decreased vision.
* Female of childbearing potential must have a negative serum pregnancy test within 28 days of randomization
* Females of child-bearing potential may participate in this trial only if using a reliable means of contraception (e.g. physical barrier (patient and partner), contraceptive pill or patch, spermicide and barrier, or intrauterine device (IUD))
* If a non-sterile male, commitment to the use of effective contraception (birth control) for the duration of the study is necessary.
* Age ≥18 years
* Diagnosis of diabetes mellitus (type 1 or type 2)
* Serum HbA1c ≥ 5.5% and ≤10% within 12 months of randomization. (It is important to be certain that the patients in the READ-4 Study have diabetes, which will suggest that the macular edema is secondary to diabetes. The American Diabetes Association has suggested that a HbA1c ≥ 5.5% may suggest the presence of diabetes mellitus.)
* Have diabetic macular edema (DME) with central subfield thickness of ≥ 310 microns on spectral domain optical coherence tomography (SD-OCT).
* Retinal thickening secondary to diabetes mellitus involving the center of the fovea (centered-involved macular edema).
* Best corrected visual acuity score in the study eye of 20/32 to 20/400 inclusive (Snellen equivalents using the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol at a distance of 4 meters). If both eyes are eligible, the investigator will select the eye to be enrolled as the study eye. There is no specific visual acuity requirement for the fellow eye at time of study eye enrollment. However, if the fellow eye is to receive ranibizumab, it must have an entry visual acuity of 20/32 to 20/400 inclusive (Snellen equivalents using the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol at a distance of 4 meters) at the time of the initial treatment.
* In the opinion of the investigator, decreased vision in the study eye is due to foveal thickening from diabetic macular edema (DME) and not from other obvious causes of decreased vision.
* Female of childbearing potential must have a negative serum pregnancy test within 28 days of randomization
* Females of child-bearing potential may participate in this trial only if using a reliable means of contraception (e.g. physical barrier (patient and partner), contraceptive pill or patch, spermicide and barrier, or intrauterine device (IUD))
* If a non-sterile male, commitment to the use of effective contraception (birth control) for the duration of the study is necessary.
Exclusion Criteria
* • Panretinal photocoagulation or macular photocoagulation within 90 days prior to Day 0 in the study eye.
* Presence of active proliferative diabetic retinopathy
* Use of any intravitreal injections (including but not limited to anti vascular endothelial growth factor therapy or steroids) within 60 days prior to Day 0 in the study eye.
* Use of Tocilizumab (IV or SC) within 180 days prior to Day 0.
* Use of intravitreal dexamethasone implant within 120 days (4 months) prior to Day 0 in the study eye.
* Use of intravitreal triamcinolone within 120 days prior to Day 0 in the study eye.
* Use of intravitreal fluocinolone implant within 3 years (36 months) prior to Day 0 in the study eye.
* Intraocular surgery within 90 days prior to Day 0 in the study eye
* History of vitrectomy in study eye
* Capsulotomy within 30 days prior to Day 0 in the study eye
* Any planned ocular surgery (including cataract extraction or capsulotomy) of the study eye anticipated within the first 180 days following Day 0;
* Pupillary dilation inadequate for quality stereoscopic fundus photography in the study eye;
* Media opacity that would limit clinical visualization;
* Presence of any form of ocular malignancy in the study eye, including choroidal melanoma
* History of herpetic infection in the study eye or adnexa
* Presence of known active or inactive toxoplasmosis in either eye
* Ocular or periocular infection in either eye
* Participation in other investigational drug or device clinical trials within 30 days prior to Day 0, or planning to participate in other investigational drug or device clinical trials within 180 days following Day 0. This includes both ocular and non-ocular clinical trials.
* Major surgery (including joint surgery) within 8 weeks prior to screening or planned major surgery within 6 months following randomization.
* Prior treatment with any cell-depleting therapies, including investigational agents or approved therapies, some examples are CAMPATH, anti-CD4, anti-CD5, anti-CD3, anti-CD19 and anti-CD20.
* Treatment with intravenous gamma globulin, plasmapheresis or Prosorba column within 6 months of baseline.
* Immunization with a live/attenuated vaccine within 4 weeks prior to baseline.
* Any previous treatment with tocilizumab.
* Any previous treatment with alkylating agents such as chlorambucil, or with total lymphoid irradiation.
Concurrent Ocular Conditions
* Proliferative diabetic retinopathy in the study eye, with the exceptions of
. Inactive, fibrotic proliferative diabetic retinopathy that has regressed following panretinal laser photocoagulation
* Vitreomacular traction or epiretinal membrane in the study eye evident biomicroscopically or by optical coherence tomography (OCT).
* Structural damage to the center of the macula in the study eye likely to preclude improvement in visual acuity following the resolution of macular edema, including atrophy of the retinal pigment epithelium, subretinal fibrosis, laser scar(s), macular ischemia, or organized hard exudate plaque
* Ocular disorders in the study eye that may confound interpretation of study results, including retinal vascular occlusion, retinal detachment, macular hole, or choroidal neovascularization of any cause (e.g., Age-related macular degeneration (AMD), ocular histoplasmosis, or pathologic myopia).
* Concurrent disease in the study eye that could compromise visual acuity or require medical or surgical intervention during the first 6-month study period
* Cataract surgery in the study eye within 3 months of study entry; Yttrium-Aluminum-Garnet (YAG) laser capsulotomy within 1 month of study entry; or any other intraocular surgery within 3 months preceding Day 0.
* History of vitreoretinal surgery in the study eye within 3 months of study entry
* Uncontrolled glaucoma (defined as intraocular pressure ≥ 30 mm) Hg despite treatment with anti-glaucoma medications)
Systemic Conditions or Exclusions for General Safety:
* Uncontrolled diabetes mellitus, as evidenced by glycosylated hemoglobin (HbA1c) value \>10%
* Blood pressure exceeding 180/100 (sitting) during the screening period
* History of severe allergic or anaphylactic reactions to human, humanized or murine monoclonal antibodies.
* Have a history of hypersensitivity to ranibizumab or any of their components
* Presence of any ulcerative wounds
* Evidence of serious uncontrolled concomitant cardiovascular, nervous system, pulmonary (including obstructive pulmonary disease), renal (including dialysis), hepatic, endocrine (include uncontrolled diabetes mellitus) or gastrointestinal disease
* History of diverticulitis, diverticulosis requiring antibiotic treatment or chronic ulcerative lower GI disease such as Crohn's disease, ulcerative colitis or other symptomatic lower GI conditions that might predispose to perforations.
* Current active liver disease as determined by principal investigator
* Known active current or history of recurrent bacterial, viral, fungal, mycobacterial or other infections (including but not limited to tuberculosis and atypical mycobacterial disease, Hepatitis B and C, and herpes zoster, but excluding fungal infections of nail beds).
* Any major episode of infection requiring hospitalization or treatment with IV antibiotics within 4 weeks of screening or oral antibiotics within 2 weeks prior to screening.
* Active Tuberculosis (TB) requiring treatment within the previous 3 years. Patients should be screened for latent Tuberculosis (TB) and, if positive, treated following local practice guidelines prior to initiating tocilizumab. Patients treated for tuberculosis with no recurrence in 3 years are permitted.
* Primary or secondary immunodeficiency (history of or currently active)
* Evidence of active malignant disease, malignancies diagnosed within the previous 5 years (including hematological malignancies and solid tumors, except basal and squamous cell carcinoma of the skin or carcinoma in situ of the cervix uteri that has been excised and cured)
* Pregnant women or nursing (breast feeding) mothers.
* Patients with reproductive potential not willing to use an effective method of contraception.
* History of alcohol, drug or chemical abuse within 1 year prior to screening.
* Patients with lack of peripheral venous access.
Subjects who meet any of the following laboratory criteria at screening should not be enrolled in the study unless the values have normalized. In addition, if any study subject meets any of the following criteria during the course of the study, the investigator can consider withholding treatment (tocilizumab and/or ranibizumab) at particular visits and initiating appropriate management, and can resume treatment with study drugs at subsequent visits once the laboratory values have normalized or once the investigator have considered that it is safe to resume therapy.
* INR ≥ 3.0 (e.g. due to current treatment with warfarin). The use of aspirin or other anticoagulants is not an exclusion
* Serum creatinine \> 1.4 mg/dL (124 μmol/L) in female patients and \> 1.6 mg/dL (141 μmol/L) in male patients. Patients with serum creatinine values exceeding limits may be eligible for the study if their estimated glomerular filtration rates (GFR) are \>30.
* Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \> 1.5 times upper limit of normal (ULN)
* Total Bilirubin \> ULN
* Platelet count \< 100 x 109/L (100,000/mm3)
* Hemoglobin \< 8.5 g/L (8.5 g/dl; 5.3 mmol/L)
* White Blood Cells \< 3.0 x 109/L (3000/mm3)
* Absolute Neutrophil Count \< 2.0 x 109/L (2000/mm3)
* Absolute Lymphocyte Count \< 0.5 x 109/L (500/mm3)
* Positive Hepatitis HBsAg, or Hepatitis C antibody
Other:
* Inability to comply with study or follow-up procedures
* Any other condition that the investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated
* Presence of active proliferative diabetic retinopathy
* Use of any intravitreal injections (including but not limited to anti vascular endothelial growth factor therapy or steroids) within 60 days prior to Day 0 in the study eye.
* Use of Tocilizumab (IV or SC) within 180 days prior to Day 0.
* Use of intravitreal dexamethasone implant within 120 days (4 months) prior to Day 0 in the study eye.
* Use of intravitreal triamcinolone within 120 days prior to Day 0 in the study eye.
* Use of intravitreal fluocinolone implant within 3 years (36 months) prior to Day 0 in the study eye.
* Intraocular surgery within 90 days prior to Day 0 in the study eye
* History of vitrectomy in study eye
* Capsulotomy within 30 days prior to Day 0 in the study eye
* Any planned ocular surgery (including cataract extraction or capsulotomy) of the study eye anticipated within the first 180 days following Day 0;
* Pupillary dilation inadequate for quality stereoscopic fundus photography in the study eye;
* Media opacity that would limit clinical visualization;
* Presence of any form of ocular malignancy in the study eye, including choroidal melanoma
* History of herpetic infection in the study eye or adnexa
* Presence of known active or inactive toxoplasmosis in either eye
* Ocular or periocular infection in either eye
* Participation in other investigational drug or device clinical trials within 30 days prior to Day 0, or planning to participate in other investigational drug or device clinical trials within 180 days following Day 0. This includes both ocular and non-ocular clinical trials.
* Major surgery (including joint surgery) within 8 weeks prior to screening or planned major surgery within 6 months following randomization.
* Prior treatment with any cell-depleting therapies, including investigational agents or approved therapies, some examples are CAMPATH, anti-CD4, anti-CD5, anti-CD3, anti-CD19 and anti-CD20.
* Treatment with intravenous gamma globulin, plasmapheresis or Prosorba column within 6 months of baseline.
* Immunization with a live/attenuated vaccine within 4 weeks prior to baseline.
* Any previous treatment with tocilizumab.
* Any previous treatment with alkylating agents such as chlorambucil, or with total lymphoid irradiation.
Concurrent Ocular Conditions
* Proliferative diabetic retinopathy in the study eye, with the exceptions of
. Inactive, fibrotic proliferative diabetic retinopathy that has regressed following panretinal laser photocoagulation
* Vitreomacular traction or epiretinal membrane in the study eye evident biomicroscopically or by optical coherence tomography (OCT).
* Structural damage to the center of the macula in the study eye likely to preclude improvement in visual acuity following the resolution of macular edema, including atrophy of the retinal pigment epithelium, subretinal fibrosis, laser scar(s), macular ischemia, or organized hard exudate plaque
* Ocular disorders in the study eye that may confound interpretation of study results, including retinal vascular occlusion, retinal detachment, macular hole, or choroidal neovascularization of any cause (e.g., Age-related macular degeneration (AMD), ocular histoplasmosis, or pathologic myopia).
* Concurrent disease in the study eye that could compromise visual acuity or require medical or surgical intervention during the first 6-month study period
* Cataract surgery in the study eye within 3 months of study entry; Yttrium-Aluminum-Garnet (YAG) laser capsulotomy within 1 month of study entry; or any other intraocular surgery within 3 months preceding Day 0.
* History of vitreoretinal surgery in the study eye within 3 months of study entry
* Uncontrolled glaucoma (defined as intraocular pressure ≥ 30 mm) Hg despite treatment with anti-glaucoma medications)
Systemic Conditions or Exclusions for General Safety:
* Uncontrolled diabetes mellitus, as evidenced by glycosylated hemoglobin (HbA1c) value \>10%
* Blood pressure exceeding 180/100 (sitting) during the screening period
* History of severe allergic or anaphylactic reactions to human, humanized or murine monoclonal antibodies.
* Have a history of hypersensitivity to ranibizumab or any of their components
* Presence of any ulcerative wounds
* Evidence of serious uncontrolled concomitant cardiovascular, nervous system, pulmonary (including obstructive pulmonary disease), renal (including dialysis), hepatic, endocrine (include uncontrolled diabetes mellitus) or gastrointestinal disease
* History of diverticulitis, diverticulosis requiring antibiotic treatment or chronic ulcerative lower GI disease such as Crohn's disease, ulcerative colitis or other symptomatic lower GI conditions that might predispose to perforations.
* Current active liver disease as determined by principal investigator
* Known active current or history of recurrent bacterial, viral, fungal, mycobacterial or other infections (including but not limited to tuberculosis and atypical mycobacterial disease, Hepatitis B and C, and herpes zoster, but excluding fungal infections of nail beds).
* Any major episode of infection requiring hospitalization or treatment with IV antibiotics within 4 weeks of screening or oral antibiotics within 2 weeks prior to screening.
* Active Tuberculosis (TB) requiring treatment within the previous 3 years. Patients should be screened for latent Tuberculosis (TB) and, if positive, treated following local practice guidelines prior to initiating tocilizumab. Patients treated for tuberculosis with no recurrence in 3 years are permitted.
* Primary or secondary immunodeficiency (history of or currently active)
* Evidence of active malignant disease, malignancies diagnosed within the previous 5 years (including hematological malignancies and solid tumors, except basal and squamous cell carcinoma of the skin or carcinoma in situ of the cervix uteri that has been excised and cured)
* Pregnant women or nursing (breast feeding) mothers.
* Patients with reproductive potential not willing to use an effective method of contraception.
* History of alcohol, drug or chemical abuse within 1 year prior to screening.
* Patients with lack of peripheral venous access.
Subjects who meet any of the following laboratory criteria at screening should not be enrolled in the study unless the values have normalized. In addition, if any study subject meets any of the following criteria during the course of the study, the investigator can consider withholding treatment (tocilizumab and/or ranibizumab) at particular visits and initiating appropriate management, and can resume treatment with study drugs at subsequent visits once the laboratory values have normalized or once the investigator have considered that it is safe to resume therapy.
* INR ≥ 3.0 (e.g. due to current treatment with warfarin). The use of aspirin or other anticoagulants is not an exclusion
* Serum creatinine \> 1.4 mg/dL (124 μmol/L) in female patients and \> 1.6 mg/dL (141 μmol/L) in male patients. Patients with serum creatinine values exceeding limits may be eligible for the study if their estimated glomerular filtration rates (GFR) are \>30.
* Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \> 1.5 times upper limit of normal (ULN)
* Total Bilirubin \> ULN
* Platelet count \< 100 x 109/L (100,000/mm3)
* Hemoglobin \< 8.5 g/L (8.5 g/dl; 5.3 mmol/L)
* White Blood Cells \< 3.0 x 109/L (3000/mm3)
* Absolute Neutrophil Count \< 2.0 x 109/L (2000/mm3)
* Absolute Lymphocyte Count \< 0.5 x 109/L (500/mm3)
* Positive Hepatitis HBsAg, or Hepatitis C antibody
Other:
* Inability to comply with study or follow-up procedures
* Any other condition that the investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Genentech, Inc.
INDUSTRY
Sponsor Role
collaborator
University of Nebraska
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Diana Do, MD
Role: PRINCIPAL_INVESTIGATOR
University of Nebraska
References
Explore related publications, articles, or registry entries linked to this study.
Bourne RR, Stevens GA, White RA, Smith JL, Flaxman SR, Price H, Jonas JB, Keeffe J, Leasher J, Naidoo K, Pesudovs K, Resnikoff S, Taylor HR; Vision Loss Expert Group. Causes of vision loss worldwide, 1990-2010: a systematic analysis. Lancet Glob Health. 2013 Dec;1(6):e339-49. doi: 10.1016/S2214-109X(13)70113-X. Epub 2013 Nov 11.
Reference Type
BACKGROUND
Klein R. Hyperglycemia and microvascular and macrovascular disease in diabetes. Diabetes Care. 1995 Feb;18(2):258-68. doi: 10.2337/diacare.18.2.258.
Reference Type
BACKGROUND
Nguyen QD, Tatlipinar S, Shah SM, Haller JA, Quinlan E, Sung J, Zimmer-Galler I, Do DV, Campochiaro PA. Vascular endothelial growth factor is a critical stimulus for diabetic macular edema. Am J Ophthalmol. 2006 Dec;142(6):961-9. doi: 10.1016/j.ajo.2006.06.068. Epub 2006 Aug 2.
Reference Type
BACKGROUND
Koskela UE, Kuusisto SM, Nissinen AE, Savolainen MJ, Liinamaa MJ. High vitreous concentration of IL-6 and IL-8, but not of adhesion molecules in relation to plasma concentrations in proliferative diabetic retinopathy. Ophthalmic Res. 2013;49(2):108-14. doi: 10.1159/000342977. Epub 2012 Dec 18.
Reference Type
BACKGROUND
Sonoda S, Sakamoto T, Yamashita T, Shirasawa M, Otsuka H, Sonoda Y. Retinal morphologic changes and concentrations of cytokines in eyes with diabetic macular edema. Retina. 2014 Apr;34(4):741-8. doi: 10.1097/IAE.0b013e3182a48917.
Reference Type
BACKGROUND
Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. Early Treatment Diabetic Retinopathy Study Report Number 2. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology. 1987 Jul;94(7):761-74. doi: 10.1016/s0161-6420(87)33527-4.
Reference Type
BACKGROUND
Boyer DS, Yoon YH, Belfort R Jr, Bandello F, Maturi RK, Augustin AJ, Li XY, Cui H, Hashad Y, Whitcup SM; Ozurdex MEAD Study Group. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology. 2014 Oct;121(10):1904-14. doi: 10.1016/j.ophtha.2014.04.024. Epub 2014 Jun 4.
Reference Type
BACKGROUND
Nguyen QD, Brown DM, Marcus DM, Boyer DS, Patel S, Feiner L, Gibson A, Sy J, Rundle AC, Hopkins JJ, Rubio RG, Ehrlich JS; RISE and RIDE Research Group. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012 Apr;119(4):789-801. doi: 10.1016/j.ophtha.2011.12.039. Epub 2012 Feb 11.
Reference Type
BACKGROUND
Arevalo JF. Diabetic macular edema: changing treatment paradigms. Curr Opin Ophthalmol. 2014 Nov;25(6):502-7. doi: 10.1097/ICU.0000000000000102.
Reference Type
BACKGROUND
Chun DW, Heier JS, Topping TM, Duker JS, Bankert JM. A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema. Ophthalmology. 2006 Oct;113(10):1706-12. doi: 10.1016/j.ophtha.2006.04.033.
Reference Type
BACKGROUND
Do DV, Nguyen QD, Khwaja AA, Channa R, Sepah YJ, Sophie R, Hafiz G, Campochiaro PA; READ-2 Study Group. Ranibizumab for edema of the macula in diabetes study: 3-year outcomes and the need for prolonged frequent treatment. JAMA Ophthalmol. 2013 Feb;131(2):139-45. doi: 10.1001/2013.jamaophthalmol.91.
Reference Type
BACKGROUND
Mesquida M, Molins B, Llorenc V, Sainz de la Maza M, Adan A. Long-term effects of tocilizumab therapy for refractory uveitis-related macular edema. Ophthalmology. 2014 Dec;121(12):2380-6. doi: 10.1016/j.ophtha.2014.06.050. Epub 2014 Sep 6.
Reference Type
BACKGROUND
Funatsu H, Yamashita H, Ikeda T, Mimura T, Eguchi S, Hori S. Vitreous levels of interleukin-6 and vascular endothelial growth factor are related to diabetic macular edema. Ophthalmology. 2003 Sep;110(9):1690-6. doi: 10.1016/S0161-6420(03)00568-2.
Reference Type
BACKGROUND
Shimizu E, Funatsu H, Yamashita H, Yamashita T, Hori S. Plasma level of interleukin-6 is an indicator for predicting diabetic macular edema. Jpn J Ophthalmol. 2002 Jan-Feb;46(1):78-83. doi: 10.1016/s0021-5155(01)00452-x.
Reference Type
BACKGROUND
Related Links
Access external resources that provide additional context or updates about the study.
https://clinicaltrials.gov/
Study of the Safety, Tolerability, and Bioactivity of Tocilizumab On Patients With Non-infectious UVEITIS: The STOP-UVEITIS Study. NCT01717170.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
0594-15-FB
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
The Effect of Intravitreal Ranibizumab on Visual Acuity and Hard Exudate Resolution in the Treatment of Diabetic Macular Edema With Center Involved Edema and Lipid Exudates
NCT02448446
COMPLETED
PHASE1/PHASE2
Efficacy Study of Lucentis in the Treatment of Diabetic Macular Edema
NCT00387582
COMPLETED
PHASE2
A Clinical Study in Current Medical Practice of the Efficacy and Safety of Ranibizumab 0.5mg in Diabetic Patients Presenting a Visual Impairment Due to Macular Edema
NCT01315275
COMPLETED
PHASE4
A 12-month, Randomized, Efficacy and Safety Study of 0.5 mg Ranibizumab vs Laser in Chinese Diabetic Macular Edema (DME) Patients
NCT02259088
COMPLETED
PHASE3
Study EvAluating Genotypes While Using Lucentis 2
NCT01464723
COMPLETED
PHASE4
Development of Intravitreal Ranibizumab by Determining the Pathogenesis of Macular Edema With Retinal Vein Occlusion
NCT02169648
UNKNOWN
NA
Treatment of Failing Blebs With Ranibizumab
NCT00570726
COMPLETED
PHASE1
Efficacy and Safety of Ranibizumab (Intravitreal Injections) Versus Laser Treatment in Patients With Visual Impairment Due to Diabetic Macular Edema
NCT00901186
COMPLETED
PHASE2
Ranibizumab and Peripheral Scatter Laser in Patients With Diabetic Macular Edema and Peripheral Nonperfusion
NCT00815360
COMPLETED
PHASE2
Frequent Dosing Regimen of Lucentis for Subjects With Persistent Diabetic Macular Edema Despite Standard antiVEGF Dosing
NCT02127684
WITHDRAWN
PHASE2
Efficacy and Safety of Ranibizumab (Intravitreal Injections) in Patients With Visual Impairment Due to Diabetic Macular Edema
NCT00989989
COMPLETED
PHASE3
Efficacy and Safety of Ranibizumab in Two "Treat and Extend" Treatment Algorithms Versus Ranibizumab As Needed in Patients With Macular Edema and Visual Impairment Secondary to Diabetes Mellitus
NCT01171976
COMPLETED
PHASE3
Change Oxygen Consumption Following Intravitreal Treatment of Lucentis (Ranibizumab) in Eyes With Diabetic Macular Edema
NCT02329132
COMPLETED
Outcomes of Subthreshold Laser Versus Intravitreal Injection of Ranibizumab in Diabetic Macular Edema
NCT04332133
COMPLETED
NA
Lucentis (Ranibizumab) in Diabetic Macular Oedema: a Treatment Evaluation
NCT01223612
COMPLETED
PHASE4
Intravitreal Ranibizumab to Treat Macular Edema After Panretinal Photocoagulation (Phase II)
NCT00668785
TERMINATED
PHASE2
Efficacy of Ranibizumab Therapy With Aflibercept in Patients With Diabetic Macular Edema
NCT02646670
COMPLETED
PHASE4
Study of Efficacy of Ranibizumab in Different Regimens in Patients With Diabetic Macula Edema
NCT02366468
COMPLETED
PHASE4
Lucentis for Macular Edema Associated With Central Retinal Vein Occlusion
NCT01028248
COMPLETED
PHASE1
Ranibizumab as a Rescue Therapy for Diabetic Macular Edema
NCT01253694
WITHDRAWN
PHASE2
Influence of Diabetes Control on Treatment of Diabetic Macular Edema With Ranibizumab
NCT02665689
TERMINATED
PHASE4
A Phase 2, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist With Ranibizumab In Adults With Diabetic Macular Edema
NCT01994291
TERMINATED
PHASE2
Efficacy and Safety of Lucentis® Use in Patients With Diabetic Macular Edema Evaluating a Spaced Out Follow-up After Intensive Treatment Phase
NCT02032173
TERMINATED
PHASE3
A Randomized Study Comparing Ranibizumab to Sham in Patients With Macular Edema Secondary to CRVO
NCT00567697
COMPLETED
PHASE3
A Safety and Efficacy Trial of a Treat and Extend Protocol Using Ranibizumab With and Without Laser Photocoagulation for Diabetic Macular Edema
NCT01934556
COMPLETED
PHASE1/PHASE2